The number of clinical trials conducted in the Asia-Pacific Rim is increasing, rising from 6% of the global total in 2005/2007 to 10% in 2011. (Clinical Trial Magnifier 2011,http://ctmagnifier.org/2011/M2011_4_01.aspx) One of the key factors driving growth is faster study start-up times compared with the West. Much of this timeline compression can be attributed to two issues: patient recruitment and regulatory approvals.
With over 60% of the world’s population living in Asia, (PriceWaterhouseCoopers 2009,http://www.pwc.be/en/pharma/The-changing-dynamics-of-pharma-outsourcing-in-Asia.pdf) one of the main reasons that trials enroll quickly is the sheer number of available patients. However, there are several other important factors that should not be overlooked. Read More